ACE/ARB Inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “ACE/ARB Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in ACE/ARB Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
ACE/ARB Inhibitors: Overview
ACE inhibitors (angiotensin converting enzyme inhibitors) and ARBs (angiotensin-receptor blockers) are used to treat high blood pressure (hypertension) and congestive heart failure, to prevent kidney failure in patients with high blood pressure or diabetes, and to reduce the risk of stroke.
Function –Angiotensin converting enzyme (ACE, EC 3.4.15.1) is a membrane-bound, zinc dependent dipeptidase that catalyzes the conversion of the decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II by removing the two C-terminal amino acids. ACE is well known to be a key part of the rennin-angiotensin system that regulates blood pressure.
ACE/ARB Inhibitors- Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) reduce intraglomerular pressure by inhibiting angiotensin II ? mediated efferent arteriolar vasoconstriction. These classes of drugs have a proteinuria-reducing effect independent of their antihypertensive effect.
ACE/ARB Inhibitors Emerging Drugs Chapters
The exact mechanism of ACE inhibitors is not fully known. They do interfere with the renin-angiotensin-aldosterone system, but their effect is not directly related to renin levels in the blood. ACE inhibitors, as the name implies, blocks an angiotensin-converting enzyme that converts angiotensin I to angiotensin II. Decreased production of angiotensin II enhances natriuresis, lowers blood pressure, and prevents remodeling of smooth muscle and cardiac myocytes. Lowered arterial and venous pressure reduces preload and afterload. Also, the hypothesis is that ACE inhibitors interfere with the degradation of bradykinin, which is a peptide that causes vasodilation.
ACE/ARB Inhibitors Emerging Drugs
Further product details are provided in the report……..
ACE/ARB Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different ACE/ARB Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
ACE/ARB Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ACE/ARB Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ACE/ARB Inhibitors drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “ACE/ARB Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in ACE/ARB Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
ACE/ARB Inhibitors: Overview
ACE inhibitors (angiotensin converting enzyme inhibitors) and ARBs (angiotensin-receptor blockers) are used to treat high blood pressure (hypertension) and congestive heart failure, to prevent kidney failure in patients with high blood pressure or diabetes, and to reduce the risk of stroke.
Function –Angiotensin converting enzyme (ACE, EC 3.4.15.1) is a membrane-bound, zinc dependent dipeptidase that catalyzes the conversion of the decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II by removing the two C-terminal amino acids. ACE is well known to be a key part of the rennin-angiotensin system that regulates blood pressure.
ACE/ARB Inhibitors- Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) reduce intraglomerular pressure by inhibiting angiotensin II ? mediated efferent arteriolar vasoconstriction. These classes of drugs have a proteinuria-reducing effect independent of their antihypertensive effect.
ACE/ARB Inhibitors Emerging Drugs Chapters
The exact mechanism of ACE inhibitors is not fully known. They do interfere with the renin-angiotensin-aldosterone system, but their effect is not directly related to renin levels in the blood. ACE inhibitors, as the name implies, blocks an angiotensin-converting enzyme that converts angiotensin I to angiotensin II. Decreased production of angiotensin II enhances natriuresis, lowers blood pressure, and prevents remodeling of smooth muscle and cardiac myocytes. Lowered arterial and venous pressure reduces preload and afterload. Also, the hypothesis is that ACE inhibitors interfere with the degradation of bradykinin, which is a peptide that causes vasodilation.
ACE/ARB Inhibitors Emerging Drugs
- Sparsentan: Travere Therapeutics
- Ezetimibe/rosuvastatin + telmisartan : Hanlim Pharm
Further product details are provided in the report……..
ACE/ARB Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different ACE/ARB Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on ACE/ARB Inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
ACE/ARB Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ACE/ARB Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ACE/ARB Inhibitors drugs.
Report Highlights
- In the coming years, the ACE/ARB Inhibitors market is set to change due to the extensive research in this filed, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence ACE/ARB Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- There are several companies involved in developing therapies for ACE/ARB Inhibitors . Launch of emerging therapies of ACE/ARB Inhibitors will significantly impact the market.
- A better understanding of the target mechanism will also contribute to the development of novel therapeutics for ACE/ARB Inhibitors .
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of ACE/ARB Inhibitors ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
- ACE/ARB Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing ACE/ARB Inhibitors drugs?
- How many ACE/ARB Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for ACE/ARB Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ACE/ARB Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for ACE/ARB Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Travere Therapeutics
- Hanlim Pharm
- Alnylam Pharmaceuticals
- Sparsentan
- Ezetimibe/rosuvastatin + telmisartan
- ALN AGT
Introduction
Executive Summary
ACE/ARB Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
ACE/ARB Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
ACE/ARB Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
ACE/ARB Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Sotorasib: Travere Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ALN AGT: Alnylam Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
ACE/ARB Inhibitors Key Companies
ACE/ARB Inhibitors Key Products
ACE/ARB Inhibitors- Unmet Needs
ACE/ARB Inhibitors- Market Drivers and Barriers
ACE/ARB Inhibitors- Future Perspectives and Conclusion
ACE/ARB Inhibitors Analyst Views
ACE/ARB Inhibitors Key Companies
Appendix
Executive Summary
ACE/ARB Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
ACE/ARB Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
ACE/ARB Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
ACE/ARB Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Sotorasib: Travere Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ALN AGT: Alnylam Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
ACE/ARB Inhibitors Key Companies
ACE/ARB Inhibitors Key Products
ACE/ARB Inhibitors- Unmet Needs
ACE/ARB Inhibitors- Market Drivers and Barriers
ACE/ARB Inhibitors- Future Perspectives and Conclusion
ACE/ARB Inhibitors Analyst Views
ACE/ARB Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for ACE/ARB Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for ACE/ARB Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for ACE/ARB Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for ACE/ARB Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
